INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
Taking everything into account, IART scores 3 out of 10 in our fundamental rating. IART was compared to 187 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. IART has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
In the past year IART had a positive cash flow from operations.
Of the past 5 years IART 4 years were profitable.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART's Return On Assets of -0.71% is fine compared to the rest of the industry. IART outperforms 71.66% of its industry peers.
The Return On Equity of IART (-1.90%) is better than 72.19% of its industry peers.
IART has a better Return On Invested Capital (4.48%) than 76.47% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IART is in line with the industry average of 7.91%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROIC | 4.48% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
With a decent Operating Margin value of 10.34%, IART is doing good in the industry, outperforming 77.54% of the companies in the same industry.
In the last couple of years the Operating Margin of IART has declined.
IART has a Gross Margin (58.47%) which is in line with its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IART is still creating some value.
IART has less shares outstanding than it did 1 year ago.
The number of shares outstanding for IART has been reduced compared to 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.13. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART's Altman-Z score of 1.13 is in line compared to the rest of the industry. IART outperforms 52.41% of its industry peers.
IART has a Debt/Equity ratio of 0.81. This is a neutral value indicating IART is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.81, IART is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.13 |
ROIC/WACC0.84
WACC5.34%
2.3 Liquidity
A Current Ratio of 1.21 indicates that IART should not have too much problems paying its short term obligations.
IART has a Current ratio of 1.21. This is amonst the worse of the industry: IART underperforms 82.89% of its industry peers.
IART has a Quick Ratio of 1.21. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.72, IART is doing worse than 89.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The earnings per share for IART have decreased strongly by -16.84% in the last year.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
IART shows a small growth in Revenue. In the last year, the Revenue has grown by 6.19%.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
3.2 Future
IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.38% yearly.
The Revenue is expected to grow by 3.92% on average over the next years.
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.98, the valuation of IART can be described as very cheap.
97.86% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.53.
IART is valuated cheaply with a Price/Forward Earnings ratio of 4.81.
98.93% of the companies in the same industry are more expensive than IART, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.71. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.98 | ||
| Fwd PE | 4.81 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IART indicates a rather cheap valuation: IART is cheaper than 95.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.84 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.05
+0.68 (+5.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.59%
Inst Owner Change-0.83%
Ins Owners3.32%
Ins Owner Change2.01%
Market Cap936.41M
Analysts54.44
Price Target17.05 (41.49%)
Short Float %10.02%
Short Ratio4.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.18%
Min EPS beat(2)-6.76%
Max EPS beat(2)11.12%
EPS beat(4)2
Avg EPS beat(4)1.7%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)2.41%
EPS beat(12)5
Avg EPS beat(12)3.04%
EPS beat(16)8
Avg EPS beat(16)4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.05%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-1.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)-0.64%
Revenue beat(8)0
Avg Revenue beat(8)-1.35%
Revenue beat(12)1
Avg Revenue beat(12)-1.19%
Revenue beat(16)3
Avg Revenue beat(16)-0.84%
PT rev (1m)0%
PT rev (3m)-36.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.98 | ||
| Fwd PE | 4.81 | ||
| P/S | 0.58 | ||
| P/FCF | N/A | ||
| P/OCF | 9.15 | ||
| P/B | 0.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.84 |
EPS(TTM)2.42
EY20.08%
EPS(NY)2.51
Fwd EY20.8%
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)1.32
OCFY10.93%
SpS20.9
BVpS19.61
TBVpS-9.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROCE | 5.36% | ||
| ROIC | 4.48% | ||
| ROICexc | 4.91% | ||
| ROICexgc | 24.71% | ||
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 86.65% | ||
| Cap/Sales | 7.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 32.45% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 1.13 |
F-Score5
WACC5.34%
ROIC/WACC0.84
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
EBIT growth 1Y-33.28%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year16.37%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-112.75%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-58.45%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%